Cafepharma Today

April 3 2025 - FDA misses approval deadline for Novavax’s COVID-19 vaccine
FDA misses approval deadline for Novavax’s COVID-19 vaccine
RFK Jr. ends public comment on HHS policies, conflicts with promised transparency
FTC halts case against CVS Caremark, OptumRx
Biotech ‘megarounds’ hold steady as startups, VCs wait on IPOs
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

AC Immune reports interim outcomes from trial of Parkinson’s therapy
Clinical Trials Arena
Thursday, April 3, 2025 - 10:15pm
tags:
AC Immune, Parkinson's Disease, clinical trials
Eli Lilly helps struggling Sangamo with $1.4B gene therapy deal
Fierce Biotech
Thursday, April 3, 2025 - 10:14pm
tags:
Sangamo Therapeutics, Eli Lilly, neurotropics, gene therapy
FDA misses approval deadline for Novavax’s COVID-19 vaccine
BioPharma Dive
Thursday, April 3, 2025 - 11:31am
tags:
FDA, Novavax, vaccines, COVID-19, chromatin regulatory system
BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpoint
Clinical Trials Arena
Thursday, April 3, 2025 - 11:29am
tags:
Biomarin, clinical trials, Palynziq, PKU
FDA Grants Fast Track Designation to Biogen’s Novel Alzheimer Disease Drug Candidate
Pharm Exec
Thursday, April 3, 2025 - 11:28am
tags:
Biogen, BIIB080, FDA, fast track, Alzheimer's disease
Sarepta’s Duchenne Gene Therapy Placed on Hold in Europe Pending Death Investigation
BioSpace
Thursday, April 3, 2025 - 11:26am
tags:
Sarepta Therapeutics, Roche, gene therapy, patient deaths, Europe, Eleviys, DMD
RFK Jr. Ends Public Comment On HHS Policies, Conflicts With Promised Transparency
Forbes
Thursday, April 3, 2025 - 11:25am
tags:
HHS, Robert F Kennedy Jr., transparency
Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy
Globe Newswire
Thursday, April 3, 2025 - 11:23am
tags:
Neurona, clinical trials, NRTX-1001, cell therapy, epilepsy
Aldeyra’s dry eye drug suffers second FDA rejection, but imminent data spur hope of fast recovery
Fierce Biotech
Thursday, April 3, 2025 - 11:20am
tags:
Aldeyra Therapeutics, dry eye disease, FDA, reproxalap
FTC halts case against CVS Caremark, OptumRx
Axios
Thursday, April 3, 2025 - 11:18am
tags:
FTC, PBMs, CVS Caremark, OptumRx
Biotech ‘megarounds’ hold steady as startups, VCs wait on IPOs
BioPharma Dive
Thursday, April 3, 2025 - 11:18am
tags:
biotech, funding, IPOs, venture capital
Novartis Has A Slight Edge On Travere — Why Analysts Aren't Worried
Investors Business Daily
Thursday, April 3, 2025 - 11:17am
tags:
Novartis, Travere Therapeutics, FDA, kidney disease, atrasentan
BeiGene abandons TIGIT antibody after lung cancer flop
Pharmaphorum
Thursday, April 3, 2025 - 10:04am
tags:
BeiGene, Tigit, ociperlimab, lung cancer, clinical trials
'Patently illegal': NIH and HHS face new lawsuit over $1.1B in revoked research grants
Fierce Biotech
Wednesday, April 2, 2025 - 7:42pm
tags:
legal, HHS, NUH, federal grant
Trump installs sweeping new tariffs, but pharma appears to dodge blow
BioPharma Dive
Wednesday, April 2, 2025 - 7:41pm
tags:
tariffs, pharma industry, Donald Trump
Former Medtronic CEO: Kennedy's HHS Leadership Is 'Quadruple Threat'
Medical Devices and Diagnostics Industry
Wednesday, April 2, 2025 - 7:37pm
tags:
Medtech, Medtronic, Bill George, HHS, Robert F Kennedy Jr.
With biosimilar competition looming, Roche takes a hit with failure of high-dose Ocrevus
Fierce Pharma
Wednesday, April 2, 2025 - 7:36pm
tags:
Ocrevus, multiple sclerosis, Roche
Elon Musk expected to step down from DOGE leadership role: Politico
Fierce Biotech
Wednesday, April 2, 2025 - 7:33pm
tags:
Elon Musk, Donald Trump, DOGE
Novo Holdings nearly doubles earnings as Wegovy swells coffers
Yahoo/Reuters
Wednesday, April 2, 2025 - 11:43am
tags:
Novo Holdings, earnings, Wegovy, Novo Nordisk
Bayer eyes launch of menopause relief, heart drugs this year
Yahoo/Reuters
Wednesday, April 2, 2025 - 11:41am
tags:
Bayer, menopause, heart failure, Beyonttra, acoramidis, elinzanetant

Pages

Latest CP Wire Articles

The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies
Sapio Sciences launches new drug discovery platform

Latest Pharmagather Articles

The Continuing Crisis, Part X: Reductions in Force, Gains in Centralized Power
In the Pipeline
A New Pan-Coronovirus Protease Inhibitor Possibility
In the Pipeline
Pain Continues to Be a Pain
In the Pipeline
Alkanes on Mars
In the Pipeline
Starving Cancer Cells Where They Live
In the Pipeline
Informa Connect’s Life Sciences Pricing & Contracting USA
Drug Channels
Evolving the Ability to Evolve
In the Pipeline
Metamorphine, An Unwelcome Product
In the Pipeline
The End of the Blockbuster Era: Unlocking Growth with Direct-to-Patient Commercialization
Drug Channels

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.